Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.64 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.64 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.54 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317924 | 1.00 | CDK5 (0.64) | CDK5CDK5R1NR1I3CYP19A1GRIN1 | |
| SCHEMBL4998837 | 1.00 | CDK5 (0.64) | CDK5CDK5R1NR1I3CYP19A1GRIN1 | |
| SCHEMBL157802 | 1.00 | CDK5 (0.64) | CDK5CDK5R1NR1I3CYP19A1GRIN1 | |
| SCHEMBL30331615 | 1.00 | CDK5 (0.64) | CDK5CDK5R1NR1I3CYP19A1GRIN1 | |
| SCHEMBL157803 | 1.00 | CDK5 (0.64) | CDK5CDK5R1NR1I3CYP19A1GRIN1 | |
| SCHEMBL24451237 | 1.00 | CDK5 (0.64) | CDK5CDK5R1NR1I3CYP19A1GRIN1 | |
| SCHEMBL4998832 | 1.00 | CDK5 (0.64) | CDK5CDK5R1NR1I3CYP19A1GRIN1 | |
| SCHEMBL10343473 | 1.00 | CDK5 (0.64) | CDK5CDK5R1NR1I3CYP19A1GRIN1 | |
| SCHEMBL11241858 | 0.98 | CDK5 (0.62) | CDK5CDK5R1NR1I3CYP19A1GRIN1 | |
| Hydrochloric Acid SCHEMBL1591866 | 0.98 | CDK5 (0.62) | CDK5CDK5R1NR1I3CYP19A1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868757-B2 | 5-β, 14-β-androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2018-01-16 | — | — | US | disclosed |
| US-20160251392-A1 | 5-Beta, 14-Beta-Androstane Derivatives Useful For The Treatment Of Proteinuria, Glomerulosclerosis And Renal Failure | SEISMIC PHARMACEUTICALS OPERATIONS LLC | 2016-09-01 | — | — | US | disclosed |
| EP-2411015-B1 | 5-BETA, 14-BETA-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEINURIA, GLOMERULOSCLEROSIS AND RENAL FAILURE | SIGMA TAU IND FARMACEUTI (IT) | 2015-12-23 | — | — | EP | disclosed |
| CN-102361643-A | 5-beta, 14-beta-androstane derivatives useful for the treatment of proteinuria, glomerulosclerosis and renal failure | SIGMA TAU IND FARMACEUTI | 2012-02-22 | — | — | CN | disclosed |
| US-20120028945-A1 | 5-Beta, 14-Beta-Androstane Derivatives Useful For The Treatment Of Proteinuria, Glomerulosclerosis And Renal Failure | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-02-02 | — | — | US | disclosed |
| EP-2411015-A1 | 5- , 14- -ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEINURIA, GLOMERULOSCLEROSIS AND RENAL FAILURE | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010108855-A1 | 5-β, 14-β-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEINURIA, GLOMERULOSCLEROSIS AND RENAL FAILURE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-30 | — | — | WO | disclosed |
| EP-0659761-B1 | New 17-iminomethylalkenyl-5beta-14beta-androstane and 17-iminoalkyl-5beta-14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | SIGMA TAU IND FARMACEUTI (IT) | 1998-04-22 | — | — | EP | disclosed |
| EP-0659761-A3 | New 17-iminomethylalkenyl-5beta-14beta-androstane and 17-iminoalkyl-5beta-14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same. | SIGMA TAU IND FARMACEUTI (IT) | 1995-12-13 | — | — | EP | disclosed |
| EP-0659761-A2 | New 17-iminomethylalkenyl-5beta-14beta-androstane and 17-iminoalkyl-5beta-14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1995-06-28 | — | — | EP | disclosed |
| EP-0583606-A3 | New hydrazono-5-beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same. | SIGMA TAU IND FARMACEUTI (IT) | 1995-04-05 | — | — | EP | disclosed |
| EP-0583606-A2 | New hydrazono-5-beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1994-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028945-A1 | 5-Beta, 14-Beta-Androstane Derivatives Useful For The Treatment Of Proteinuria, Glomerulosclerosis And Renal Failure | NR5A1, SRD5A2, SHBG | CDK5 68/4885CDK5R1 133/4885NR1I3 169/4885 |
| US-20160251392-A1 | 5-Beta, 14-Beta-Androstane Derivatives Useful For The Treatment Of Proteinuria, Glomerulosclerosis And Renal Failure | NR5A1, SRD5A2, SHBG | CDK5 68/4885CDK5R1 133/4885NR1I3 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.